FDA granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of metastatic non-small cell lung cancer.
FDA granted orphan drug designation to ADXS-HPV for the treatment of stage II-IV invasive cervical cancer. ADXS-HPV is an immunotherapy drug candidate, developed by Advaxis Inc., which is designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into... […]
KRISTIN DARBY was named chief information officer of Cancer Treatment Centers of America. She will be the principal architect of the organization's Information Services function, including all clinical and non-clinical hardware and software applications, data infrastructure, warehousing and security, informatics, and system-wide technology support services.
THE MELANOMA RESEARCH ALLIANCE and L'Oreal Paris launched It's THAT Worth It, a campaign to support melanoma research.
THE JOHNS HOPKINS Kimmel Cancer Center received $10 million from Under Armour to help build a breast health center. The gift comes from the company's Power in Pink Campaign, and the facility will be named the Under Armour LiveWell Center.
ELI LILLY & COMPANY signed an agreement with Prasco Laboratories to market the authorized generic version of Evista (raloxifene hydrochloride tablets), in 60 mg strength in the U.S. Prasco will begin shipping the product immediately. The financial terms of the agreement were not disclosed.
THE ATHENA BREAST HEALTH NETWORK adopted the Health Level Seven International-approved guide for sharing electronic data for breast cancer treatment. The guide was developed by the American Society for Clinical Oncology and approved through HL7 to become a national data standard.
DAVID COLE was named president of The Medical University of South Carolina and its affiliated medical centers.
THE US ONCOLOGY NETWORK and the Community Oncology Alliance sponsored a “Virtual Hill Day” to persuade members of Congress to stop the Centers for Medicare and Medicaid Services from applying the sequester cut to Medicare payments for cancer care drugs.
A study by a conservative think tank found large differences in performance of the FDA divisions, with oncology demonstrating the agency's fastest time from application submission to approval.
